More Evidence COVID 'Brain Fog' Is Biologically Based

Kelli Whitlock Burton
April 01, 2022

Patients with persistent cognitive impairment months after illness with mild COVID-19 have higher levels of inflammatory markers in their cerebrospinal fluid (CSF).

Researchers found elevated levels of CSF immune activation and immunovascular markers in individuals with cognitive post-acute sequelae of SARS-CoV-2 infection (PASC). Patients whose cognitive symptoms developed during the acute phase of COVID-19 had the highest levels of brain inflammation.

The findings add to a growing body of evidence that suggests the condition often referred to as "brain fog" has a neurological basis, said lead author Joanna Hellmuth, MD, MHS, assistant professor of neurology at the University of California, San Francisco Weill Institute of Neurosciences and the UCSF Memory and Aging Center.

The findings will be presented at the American Academy of Neurology (AAN) 2022 Annual Meeting on Thursday.

Inflammatory Response

There are no effective diagnostic tests or treatments for cognitive PASC, which prompted the investigators to study inflammation in patients with the condition. As reported by Medscape Medical News, the same investigators published initial findings earlier this year. This research showed abnormalities in the CSF in 77% of patients with cognitive impairment. Patients without cognitive impairments had normal CSF.

Extending that work in this new study, researchers studied patients from the Long-term Impact of Infection with Novel Coronavirus (LIINC) study with confirmed SARS-CoV-2 infection who were not hospitalized. They conducted 2-hour neurocognitive interviews and identified 23 people with new, persistent cognitive symptoms (cognitive PASC) and 10 with no cognitive symptoms who served as controls.

All participants underwent additional neurologic examination and neuropsychological testing, and half agreed to a lumbar puncture to allow researchers to collect CSF samples. The CSF was collected a median of 10.2 months after initial COVID symptoms began.

Participants with cognitive PASC had higher median levels of CSF acute phase reactants C-reactive protein (0.007 mg/L vs 0.000 mg/L; P =.004) and serum amyloid A (0.001 mg/L vs 0.000 mg/L; P = .001) compared with COVID controls.

The PASC group also had elevated levels of CSF immune activation markers interferon-gamma-inducible protein, interleukin-8, and immunovascular markers vascular endothelial growth factor-C and VEGFR-1, although the differences with the control group were not statistically significant.

The timing of the onset of cognitive problems was also associated with higher levels of immune activation and immunovascular markers. Patients with brain fog that developed during the acute phase of COVID-19 had higher levels of CSF VEGF-C compared with patients whose cognitive symptoms developed more than a month after initial COVID symptoms (173 pg/mL vs 99 pg/mL; P = .048) and COVID controls (79 pg/mL; P = .048).

Acute onset cognitive PASC participants had higher CSF levels of IP-10 (P=.030), IL-8 (P = .048), placental growth factor (P = .030) and intercellular adhesion molecule-1 (P = .045) compared with COVID controls.

Researchers believe these new findings could mean that intrathecal immune activation and endothelial activation/dysfunction may contribute to cognitive PASC and that the mechanisms involved may be different in patients with acute cognitive PASC vs those with delayed onset.

"Our data suggests that perhaps in these people with more acute cognitive changes they don't have the return to homeostasis," Hellmuth said, while patients with delayed onset cognitive PASC had levels more in line with COVID patients who had no cognitive issues.

Moving the Needle Forward

Commenting on the findings for Medscape Medical News, William Schaffner, MD, professor of infectious diseases, Vanderbilt University Medical Center, Nashville, Tennessee, said that while the study doesn't rule out a possible psychological basis for cognitive PASC, it adds more weight to the biological argument.

"When you have nonspecific symptoms for which specific tests are unavailable," Schaffner explained, "there is a natural question that always comes up: Is this principally a biologically induced phenomenon or psychological? This moves the needle substantially in the direction of a biological phenomenon."

Another important element to the study, Schaffner said, is that the patients involved had mild COVID.

"Not every patient with long COVID symptoms had been hospitalized with severe disease," he said. "There are inflammatory phenomenon in various organ systems such that even if the inflammatory response in the lung was not severe enough to get you into the hospital, there were inflammatory responses in other organ systems that could persist once the acute infection resolved."

Although the small size of the study is a limitation, Schaffner said that shouldn't minimize the importance of these findings.

"That it's small doesn't diminish its value," he said. "The next step forward might be to try to associate the markers more specifically with COVID. The more precise we can be, the more convincing the story will become."

The study was funded by the National Institutes of Health. Hellmuth received grant support from the National Institutes of Health/NIMH supporting this work and personal fees for medical-legal consultation outside of the submitted work. Schaffner has disclosed no relevant financial relationships.

Health Solutions From Our Sponsors

Reviewed on 4/4/2022
References
SOURCE: Medscape, April 01, 2022. American Academy of Neurology (AAN) 2021 Annual Meeting. Abstract 1162. To be presented April 7, 2022.

Health Solutions From Our Sponsors